278 related articles for article (PubMed ID: 24842760)
1. Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract.
Tseng D; Kim J; Warrick A; Nelson D; Pukay M; Beadling C; Heinrich M; Selim MA; Corless CL; Nelson K
J Am Acad Dermatol; 2014 Aug; 71(2):229-36. PubMed ID: 24842760
[TBL] [Abstract][Full Text] [Related]
2. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W
J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561
[TBL] [Abstract][Full Text] [Related]
3. BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi.
Francis JH; Grossniklaus HE; Habib LA; Marr B; Abramson DH; Busam KJ
Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):117-121. PubMed ID: 29332123
[TBL] [Abstract][Full Text] [Related]
4. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA
Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725
[TBL] [Abstract][Full Text] [Related]
5. NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi.
Tschandl P; Berghoff AS; Preusser M; Burgstaller-Muehlbacher S; Pehamberger H; Okamoto I; Kittler H
PLoS One; 2013; 8(7):e69639. PubMed ID: 23861977
[TBL] [Abstract][Full Text] [Related]
6. High frequency of PTEN mutations in nevi and melanomas from xeroderma pigmentosum patients.
Masaki T; Wang Y; DiGiovanna JJ; Khan SG; Raffeld M; Beltaifa S; Hornyak TJ; Darling TN; Lee CC; Kraemer KH
Pigment Cell Melanoma Res; 2014 May; 27(3):454-64. PubMed ID: 24483290
[TBL] [Abstract][Full Text] [Related]
7. BRAF and NRAS mutations in melanoma and melanocytic nevi.
Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
[TBL] [Abstract][Full Text] [Related]
8. BRAF and GNAQ mutations in melanocytic tumors of the oral cavity.
Cohen Y; Goldenberg-Cohen N; Akrish S; Shani T; Amariglio N; Dratviman-Storobinsky O; Kaplan I; Barshack I; Hirshberg A
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Dec; 114(6):778-84. PubMed ID: 23159116
[TBL] [Abstract][Full Text] [Related]
9. Proliferative nodules arising within congenital melanocytic nevi: a histologic, immunohistochemical, and molecular analyses of 43 cases.
Phadke PA; Rakheja D; Le LP; Selim MA; Kapur P; Davis A; Mihm MC; Hoang MP
Am J Surg Pathol; 2011 May; 35(5):656-69. PubMed ID: 21436676
[TBL] [Abstract][Full Text] [Related]
10. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases.
Öztürk Sari Ş; Yilmaz İ; Taşkin OÇ; Narli G; Şen F; Çomoğlu Ş; Firat P; Bİlgİç B; Yilmazbayhan D; Özlük Y; Büyükbabanİ N
Pathology; 2017 Jan; 49(1):55-61. PubMed ID: 27914687
[TBL] [Abstract][Full Text] [Related]
11. Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.
Chraybi M; Abd Alsamad I; Copie-Bergman C; Baia M; André J; Dumaz N; Ortonne N
Hum Pathol; 2013 Sep; 44(9):1902-11. PubMed ID: 23664541
[TBL] [Abstract][Full Text] [Related]
12. Genetic Background of Iris Melanomas and Iris Melanocytic Tumors of Uncertain Malignant Potential.
van Poppelen NM; Vaarwater J; Mudhar HS; Sisley K; Rennie IG; Rundle P; Brands T; van den Bosch QCC; Mensink HW; de Klein A; Kiliç E; Verdijk RM
Ophthalmology; 2018 Jun; 125(6):904-912. PubMed ID: 29371009
[TBL] [Abstract][Full Text] [Related]
13. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 Mutation Profile and Histomorphological Analysis of Anorectal Melanomas: A Clinicopathologic Study.
Taskin OC; Sari SO; Yilmaz I; Hurdogan O; Keskin M; Buyukbabani N; Gulluoglu M
Turk Patoloji Derg; 2023; 39(1):23-30. PubMed ID: 35642348
[TBL] [Abstract][Full Text] [Related]
14. Mutations in GNA11 in uveal melanoma.
Van Raamsdonk CD; Griewank KG; Crosby MB; Garrido MC; Vemula S; Wiesner T; Obenauf AC; Wackernagel W; Green G; Bouvier N; Sozen MM; Baimukanova G; Roy R; Heguy A; Dolgalev I; Khanin R; Busam K; Speicher MR; O'Brien J; Bastian BC
N Engl J Med; 2010 Dec; 363(23):2191-9. PubMed ID: 21083380
[TBL] [Abstract][Full Text] [Related]
15. Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi.
Möller I; Murali R; Müller H; Wiesner T; Jackett LA; Scholz SL; Cosgarea I; van de Nes JA; Sucker A; Hillen U; Schilling B; Paschen A; Kutzner H; Rütten A; Böckers M; Scolyer RA; Schadendorf D; Griewank KG
Mod Pathol; 2017 Mar; 30(3):350-356. PubMed ID: 27934878
[TBL] [Abstract][Full Text] [Related]
16. Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris Melanoma.
Scholz SL; Möller I; Reis H; Süßkind D; van de Nes JAP; Leonardelli S; Schilling B; Livingstone E; Schimming T; Paschen A; Sucker A; Murali R; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3464-3470. PubMed ID: 28700778
[TBL] [Abstract][Full Text] [Related]
17. GNA11 and N-RAS mutations: alternatives for MAPK pathway activating GNAQ mutations in primary melanocytic tumours of the central nervous system.
Gessi M; Hammes J; Lauriola L; Dörner E; Kirfel J; Kristiansen G; zur Muehlen A; Denkhaus D; Waha A; Pietsch T
Neuropathol Appl Neurobiol; 2013 Jun; 39(4):417-25. PubMed ID: 22758774
[TBL] [Abstract][Full Text] [Related]
18. Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system.
Küsters-Vandevelde HV; Klaasen A; Küsters B; Groenen PJ; van Engen-van Grunsven IA; van Dijk MR; Reifenberger G; Wesseling P; Blokx WA
Acta Neuropathol; 2010 Mar; 119(3):317-23. PubMed ID: 19936769
[TBL] [Abstract][Full Text] [Related]
19. KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases.
Zebary A; Jangard M; Omholt K; Ragnarsson-Olding B; Hansson J
Br J Cancer; 2013 Aug; 109(3):559-64. PubMed ID: 23860532
[TBL] [Abstract][Full Text] [Related]
20. Low mutational burden of eight genes involved in the MAPK/ERK, PI3K/AKT, and GNAQ/11 pathways in female genital tract primary melanomas.
Pappa KI; Vlachos GD; Roubelakis M; Vlachos DE; Kalafati TG; Loutradis D; Anagnou NP
Biomed Res Int; 2015; 2015():303791. PubMed ID: 25695059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
